Shilpa Medicare Ltd. has announced plans to develop and manufacture biosimilars in India, while its subsidiary Shilpa Biologicals partners with SteinCares to commercialize these therapies across Latin America. The collaboration aims to enhance global access to affordable biologics, strengthening Shilpa’s footprint in the fast-growing biosimilars market.
Shilpa Medicare Ltd., a leading Indian pharmaceutical company, is advancing its biosimilars strategy with a dual focus: domestic manufacturing in India and international commercialization in Latin America. Through its subsidiary Shilpa Biologicals, the company has partnered with SteinCares, a specialty healthcare firm, to distribute biosimilars across Latin America.
This collaboration is expected to broaden patient access to cost-effective biologics, particularly for chronic conditions such as autoimmune and inflammatory diseases. By leveraging Shilpa’s manufacturing expertise and SteinCares’ regional distribution strength, the partnership positions both companies to capture significant market share in the global biosimilars segment.
Industry analysts highlight that biosimilars are increasingly vital in reducing healthcare costs while maintaining treatment efficacy, making this move strategically important for Shilpa Medicare’s growth trajectory.
Key Highlights
-
Manufacturing: Shilpa Medicare to produce biosimilars in India
-
Partnership: Shilpa Biologicals collaborates with SteinCares for Latin America commercialization
-
Market Focus: Chronic diseases including autoimmune and inflammatory conditions
-
Strategic Impact: Expands Shilpa’s global footprint in biosimilars
-
Healthcare Benefit: Enhances affordability and accessibility of biologic therapies
Source: PR Newswire, American Pharmaceutical Review, SteinCares Corporate Update